SlideShare a Scribd company logo
Decreased initiation of usual activities in people with mild-moderate Alzheimer's disease: a descriptive analysis from the VISTA clinical trial Cheryl Cook, Sherri Fay, Kenneth Rockwood (Dalhousie University, Halifax, NS, Canada)
The VISTA Study ,[object Object],[object Object],[object Object],[object Object],[object Object]
VISTA - Primary Objectives ,[object Object],[object Object],CMAJ  2006;174:1099-1105
Trial Design ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],CMAJ  2006;174:1099-1105 Interviews digitally video recorded
Patient Disposition Galantamine (n=64) Placebo (n=66) Completed 4 Months (n=56) Completed  8 Months (n=47) Completed 8 Months (n=49) Screen Failures  (n=29) Did not meet inclusion criteria (n=23) Withdrew consent  (n=3) Other reasons (n=3) Withdrawals  (n=11) Adverse Event (AE) (n=5) Noncompliance  (n=3) Insufficient response (n=2)  Lost to follow-up (n=1) Withdrawals  (n=6) A E  (n=3) Insufficient response  (n=1) Withdrew consent (n=1) Moved (n=1) Withdrawals  (n=7) A E  (n=5) Withdrew Consent  (n=1) site closure (n=1) CMAJ  2006;174:1099-1105 Completed 4 months (n=53) Placebo controlled Open-label Randomized  (n=130) Withdrawals  (n=10) A E  (n=2) Non-compliance  (n=3) Insufficient response  (n=2) Withdrew consent (n=2) Death (n=1) Assessed for eligibility (n=159)
Baseline Characteristics CMAJ  2006;174:1099-1105
Secondary Analysis:  Decreased Initiation ,[object Object],[object Object],[object Object]
Overview ,[object Object],[object Object],[object Object],[object Object]
Methods – secondary analysis ,[object Object],[object Object],[object Object]
Methods – secondary analysis ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Decreased initiation ,[object Object],[object Object],[object Object]
Figure 1.  Proportion of patients by type of decreased initiation
Figure 2.  Proportion of patients with decreased initiation by domain affected
Area affected by decreased initiation ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Other factors ,[object Object],[object Object]
Figure 3.  Patients with decreased initiation by domain and co-occurring problem
Strategies ,[object Object],[object Object],[object Object],[object Object],[object Object]
DISCUSSION ,[object Object],[object Object],[object Object],[object Object]

More Related Content

What's hot

Journal club
Journal clubJournal club
Journal club
vinodksahu
 
Dose response and efficacy of spinal manipulation for care of chronic low bac...
Dose response and efficacy of spinal manipulation for care of chronic low bac...Dose response and efficacy of spinal manipulation for care of chronic low bac...
Dose response and efficacy of spinal manipulation for care of chronic low bac...
Younis I Munshi
 
Bipolar Disorder in Primary Care
Bipolar Disorder in Primary CareBipolar Disorder in Primary Care
Bipolar Disorder in Primary Care
Andri Andri
 
Measuring the right outcomes in mental health
Measuring the right outcomes in mental healthMeasuring the right outcomes in mental health
Measuring the right outcomes in mental health
John Brazier
 
Deutetrabenazine, a drug for Tardive Dyskinesia
Deutetrabenazine, a drug for Tardive DyskinesiaDeutetrabenazine, a drug for Tardive Dyskinesia
Deutetrabenazine, a drug for Tardive Dyskinesia
Ilkin Bakirli
 
J.Clin_.Psychiatry
J.Clin_.PsychiatryJ.Clin_.Psychiatry
J.Clin_.Psychiatry
Larry Macke, ELS
 
Milestone studies
Milestone studiesMilestone studies
Milestone studies
Priyash Jain
 
AcademyHealth 2015, Values and Side-effects--Veazie
AcademyHealth 2015, Values and Side-effects--VeazieAcademyHealth 2015, Values and Side-effects--Veazie
AcademyHealth 2015, Values and Side-effects--Veazie
Julia Weaver
 
Sof stat issues_pro
Sof stat issues_proSof stat issues_pro
Sof stat issues_pro
Jonas Ranstam PhD
 
Delay discounting
Delay discountingDelay discounting
Delay discounting
BARRY STANLEY 2 fasd
 
Tabalumab rrms aan_poster_27_march_2018_clear__kp-28_mar2018_new__-_revised (1)
Tabalumab rrms aan_poster_27_march_2018_clear__kp-28_mar2018_new__-_revised (1)Tabalumab rrms aan_poster_27_march_2018_clear__kp-28_mar2018_new__-_revised (1)
Tabalumab rrms aan_poster_27_march_2018_clear__kp-28_mar2018_new__-_revised (1)
BartsMSBlog
 

What's hot (11)

Journal club
Journal clubJournal club
Journal club
 
Dose response and efficacy of spinal manipulation for care of chronic low bac...
Dose response and efficacy of spinal manipulation for care of chronic low bac...Dose response and efficacy of spinal manipulation for care of chronic low bac...
Dose response and efficacy of spinal manipulation for care of chronic low bac...
 
Bipolar Disorder in Primary Care
Bipolar Disorder in Primary CareBipolar Disorder in Primary Care
Bipolar Disorder in Primary Care
 
Measuring the right outcomes in mental health
Measuring the right outcomes in mental healthMeasuring the right outcomes in mental health
Measuring the right outcomes in mental health
 
Deutetrabenazine, a drug for Tardive Dyskinesia
Deutetrabenazine, a drug for Tardive DyskinesiaDeutetrabenazine, a drug for Tardive Dyskinesia
Deutetrabenazine, a drug for Tardive Dyskinesia
 
J.Clin_.Psychiatry
J.Clin_.PsychiatryJ.Clin_.Psychiatry
J.Clin_.Psychiatry
 
Milestone studies
Milestone studiesMilestone studies
Milestone studies
 
AcademyHealth 2015, Values and Side-effects--Veazie
AcademyHealth 2015, Values and Side-effects--VeazieAcademyHealth 2015, Values and Side-effects--Veazie
AcademyHealth 2015, Values and Side-effects--Veazie
 
Sof stat issues_pro
Sof stat issues_proSof stat issues_pro
Sof stat issues_pro
 
Delay discounting
Delay discountingDelay discounting
Delay discounting
 
Tabalumab rrms aan_poster_27_march_2018_clear__kp-28_mar2018_new__-_revised (1)
Tabalumab rrms aan_poster_27_march_2018_clear__kp-28_mar2018_new__-_revised (1)Tabalumab rrms aan_poster_27_march_2018_clear__kp-28_mar2018_new__-_revised (1)
Tabalumab rrms aan_poster_27_march_2018_clear__kp-28_mar2018_new__-_revised (1)
 

Similar to Decreased initiation for activities in mild/moderate Alzheimer's disease patients

Part IV Data Collection Procedures & Measurement ToolsInstrument.docx
Part IV Data Collection Procedures & Measurement ToolsInstrument.docxPart IV Data Collection Procedures & Measurement ToolsInstrument.docx
Part IV Data Collection Procedures & Measurement ToolsInstrument.docx
ssuser562afc1
 
Non-adherence In Chronic Myeloid Leukemia: Results Of A Global Survey Of 2546...
Non-adherence In Chronic Myeloid Leukemia: Results Of A Global Survey Of 2546...Non-adherence In Chronic Myeloid Leukemia: Results Of A Global Survey Of 2546...
Non-adherence In Chronic Myeloid Leukemia: Results Of A Global Survey Of 2546...
jangeissler
 
Assessing Disability
Assessing DisabilityAssessing Disability
Assessing Disability
lmk1970
 
Therese jackson
Therese jacksonTherese jackson
Therese jackson
COT SSNP
 
ECTRIMS 'burning debate' pk coyle
ECTRIMS 'burning debate' pk coyleECTRIMS 'burning debate' pk coyle
ECTRIMS 'burning debate' pk coyle
Klaus Schmierer
 
Experimental study on alzhimer
Experimental study on alzhimerExperimental study on alzhimer
Master of Public Health.docx
Master of Public Health.docxMaster of Public Health.docx
Master of Public Health.docx
write4
 
presentation-efficacy-effectiveness-models_en.pdf
presentation-efficacy-effectiveness-models_en.pdfpresentation-efficacy-effectiveness-models_en.pdf
presentation-efficacy-effectiveness-models_en.pdf
havoc2003
 
Urmimala Sarkar: Health IT-enabled self-management support for vulnerable pat...
Urmimala Sarkar: Health IT-enabled self-management support for vulnerable pat...Urmimala Sarkar: Health IT-enabled self-management support for vulnerable pat...
Urmimala Sarkar: Health IT-enabled self-management support for vulnerable pat...
aimlabstanford
 
Low Back Pain & Sciatica
Low Back Pain & Sciatica Low Back Pain & Sciatica
Low Back Pain & Sciatica
Alaa Eddeen Al-Qaisi
 
Long term effects of cognitive training
Long term effects of cognitive trainingLong term effects of cognitive training
Long term effects of cognitive training
MiriamTrapagaO
 
Work related musculoskeletal disorders in physical therapists
Work related musculoskeletal disorders in physical therapistsWork related musculoskeletal disorders in physical therapists
Work related musculoskeletal disorders in physical therapists
Tuğçehan Kara
 
Update on cognitive remediation
Update on cognitive remediationUpdate on cognitive remediation
Update on cognitive remediation
Najib Alwi
 
PROFESSOR JONATHAN CHICK - ANTIPATHY OR NAIVETY: 12-STEP FACILITATION IN UK H...
PROFESSOR JONATHAN CHICK - ANTIPATHY OR NAIVETY: 12-STEP FACILITATION IN UK H...PROFESSOR JONATHAN CHICK - ANTIPATHY OR NAIVETY: 12-STEP FACILITATION IN UK H...
PROFESSOR JONATHAN CHICK - ANTIPATHY OR NAIVETY: 12-STEP FACILITATION IN UK H...
iCAADEvents
 
Comparison of remission criteria in a tumour necrosis factor inhibitor treate...
Comparison of remission criteria in a tumour necrosis factor inhibitor treate...Comparison of remission criteria in a tumour necrosis factor inhibitor treate...
Comparison of remission criteria in a tumour necrosis factor inhibitor treate...
Younis I Munshi
 
EPIDEMIOLOGY OF PERIODONTAL DISEASE DR SINDHURA.ppt
EPIDEMIOLOGY OF PERIODONTAL DISEASE DR SINDHURA.pptEPIDEMIOLOGY OF PERIODONTAL DISEASE DR SINDHURA.ppt
EPIDEMIOLOGY OF PERIODONTAL DISEASE DR SINDHURA.ppt
DentalYoutube
 
Me? or meds?  subjective symptoms in medicated and unmedicated adults with adhd
Me? or meds?  subjective symptoms in medicated and unmedicated adults with adhd Me? or meds?  subjective symptoms in medicated and unmedicated adults with adhd
Me? or meds?  subjective symptoms in medicated and unmedicated adults with adhd
Jhovana Cervantes
 
APS 2016
APS 2016APS 2016
APS 2016
Alexandra Gabor
 
Master of Public Health.pdf
Master of Public Health.pdfMaster of Public Health.pdf
Master of Public Health.pdf
bkbk37
 
ALS CBS Manual Instructions - Revised
ALS CBS Manual Instructions - RevisedALS CBS Manual Instructions - Revised
ALS CBS Manual Instructions - Revised
The ALS Association
 

Similar to Decreased initiation for activities in mild/moderate Alzheimer's disease patients (20)

Part IV Data Collection Procedures & Measurement ToolsInstrument.docx
Part IV Data Collection Procedures & Measurement ToolsInstrument.docxPart IV Data Collection Procedures & Measurement ToolsInstrument.docx
Part IV Data Collection Procedures & Measurement ToolsInstrument.docx
 
Non-adherence In Chronic Myeloid Leukemia: Results Of A Global Survey Of 2546...
Non-adherence In Chronic Myeloid Leukemia: Results Of A Global Survey Of 2546...Non-adherence In Chronic Myeloid Leukemia: Results Of A Global Survey Of 2546...
Non-adherence In Chronic Myeloid Leukemia: Results Of A Global Survey Of 2546...
 
Assessing Disability
Assessing DisabilityAssessing Disability
Assessing Disability
 
Therese jackson
Therese jacksonTherese jackson
Therese jackson
 
ECTRIMS 'burning debate' pk coyle
ECTRIMS 'burning debate' pk coyleECTRIMS 'burning debate' pk coyle
ECTRIMS 'burning debate' pk coyle
 
Experimental study on alzhimer
Experimental study on alzhimerExperimental study on alzhimer
Experimental study on alzhimer
 
Master of Public Health.docx
Master of Public Health.docxMaster of Public Health.docx
Master of Public Health.docx
 
presentation-efficacy-effectiveness-models_en.pdf
presentation-efficacy-effectiveness-models_en.pdfpresentation-efficacy-effectiveness-models_en.pdf
presentation-efficacy-effectiveness-models_en.pdf
 
Urmimala Sarkar: Health IT-enabled self-management support for vulnerable pat...
Urmimala Sarkar: Health IT-enabled self-management support for vulnerable pat...Urmimala Sarkar: Health IT-enabled self-management support for vulnerable pat...
Urmimala Sarkar: Health IT-enabled self-management support for vulnerable pat...
 
Low Back Pain & Sciatica
Low Back Pain & Sciatica Low Back Pain & Sciatica
Low Back Pain & Sciatica
 
Long term effects of cognitive training
Long term effects of cognitive trainingLong term effects of cognitive training
Long term effects of cognitive training
 
Work related musculoskeletal disorders in physical therapists
Work related musculoskeletal disorders in physical therapistsWork related musculoskeletal disorders in physical therapists
Work related musculoskeletal disorders in physical therapists
 
Update on cognitive remediation
Update on cognitive remediationUpdate on cognitive remediation
Update on cognitive remediation
 
PROFESSOR JONATHAN CHICK - ANTIPATHY OR NAIVETY: 12-STEP FACILITATION IN UK H...
PROFESSOR JONATHAN CHICK - ANTIPATHY OR NAIVETY: 12-STEP FACILITATION IN UK H...PROFESSOR JONATHAN CHICK - ANTIPATHY OR NAIVETY: 12-STEP FACILITATION IN UK H...
PROFESSOR JONATHAN CHICK - ANTIPATHY OR NAIVETY: 12-STEP FACILITATION IN UK H...
 
Comparison of remission criteria in a tumour necrosis factor inhibitor treate...
Comparison of remission criteria in a tumour necrosis factor inhibitor treate...Comparison of remission criteria in a tumour necrosis factor inhibitor treate...
Comparison of remission criteria in a tumour necrosis factor inhibitor treate...
 
EPIDEMIOLOGY OF PERIODONTAL DISEASE DR SINDHURA.ppt
EPIDEMIOLOGY OF PERIODONTAL DISEASE DR SINDHURA.pptEPIDEMIOLOGY OF PERIODONTAL DISEASE DR SINDHURA.ppt
EPIDEMIOLOGY OF PERIODONTAL DISEASE DR SINDHURA.ppt
 
Me? or meds?  subjective symptoms in medicated and unmedicated adults with adhd
Me? or meds?  subjective symptoms in medicated and unmedicated adults with adhd Me? or meds?  subjective symptoms in medicated and unmedicated adults with adhd
Me? or meds?  subjective symptoms in medicated and unmedicated adults with adhd
 
APS 2016
APS 2016APS 2016
APS 2016
 
Master of Public Health.pdf
Master of Public Health.pdfMaster of Public Health.pdf
Master of Public Health.pdf
 
ALS CBS Manual Instructions - Revised
ALS CBS Manual Instructions - RevisedALS CBS Manual Instructions - Revised
ALS CBS Manual Instructions - Revised
 

Recently uploaded

vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
Dr.pavithra Anandan
 
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
NephroTube - Dr.Gawad
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
Jim Jacob Roy
 
Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
reignlana06
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
rishi2789
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Holistified Wellness
 
10 Benefits an EPCR Software should Bring to EMS Organizations
10 Benefits an EPCR Software should Bring to EMS Organizations   10 Benefits an EPCR Software should Bring to EMS Organizations
10 Benefits an EPCR Software should Bring to EMS Organizations
Traumasoft LLC
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
HongBiThi1
 
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptxCLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
Government Dental College & Hospital Srinagar
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
LaniyaNasrink
 
pathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathologypathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathology
ZayedKhan38
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
PsychoTech Services
 
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Kosmoderma Academy Of Aesthetic Medicine
 
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan PatroJune 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
Kanhu Charan
 
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHYMERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
DRPREETHIJAMESP
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
Josep Vidal-Alaball
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
Dr. Jyothirmai Paindla
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
Health Advances
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Tina Purnat
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
MedicoseAcademics
 

Recently uploaded (20)

vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
 
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
 
Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
 
10 Benefits an EPCR Software should Bring to EMS Organizations
10 Benefits an EPCR Software should Bring to EMS Organizations   10 Benefits an EPCR Software should Bring to EMS Organizations
10 Benefits an EPCR Software should Bring to EMS Organizations
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
 
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptxCLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
 
pathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathologypathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathology
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
 
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
 
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan PatroJune 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
 
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHYMERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
 

Decreased initiation for activities in mild/moderate Alzheimer's disease patients

  • 1. Decreased initiation of usual activities in people with mild-moderate Alzheimer's disease: a descriptive analysis from the VISTA clinical trial Cheryl Cook, Sherri Fay, Kenneth Rockwood (Dalhousie University, Halifax, NS, Canada)
  • 2.
  • 3.
  • 4.
  • 5. Patient Disposition Galantamine (n=64) Placebo (n=66) Completed 4 Months (n=56) Completed 8 Months (n=47) Completed 8 Months (n=49) Screen Failures (n=29) Did not meet inclusion criteria (n=23) Withdrew consent (n=3) Other reasons (n=3) Withdrawals (n=11) Adverse Event (AE) (n=5) Noncompliance (n=3) Insufficient response (n=2) Lost to follow-up (n=1) Withdrawals (n=6) A E (n=3) Insufficient response (n=1) Withdrew consent (n=1) Moved (n=1) Withdrawals (n=7) A E (n=5) Withdrew Consent (n=1) site closure (n=1) CMAJ 2006;174:1099-1105 Completed 4 months (n=53) Placebo controlled Open-label Randomized (n=130) Withdrawals (n=10) A E (n=2) Non-compliance (n=3) Insufficient response (n=2) Withdrew consent (n=2) Death (n=1) Assessed for eligibility (n=159)
  • 6. Baseline Characteristics CMAJ 2006;174:1099-1105
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12. Figure 1. Proportion of patients by type of decreased initiation
  • 13. Figure 2. Proportion of patients with decreased initiation by domain affected
  • 14.
  • 15.
  • 16. Figure 3. Patients with decreased initiation by domain and co-occurring problem
  • 17.
  • 18.

Editor's Notes

  1. familiarisation (watching the interviews, reading the text-based data and making notations about the data ), identifying thematic framework (identifying key issues and themes related to the a priori objectives of the study as well as those that emerge from the data – these are the basis for code formulation), indexing (applying codes to the data to mark occurrences of the concepts derived in the previous stage), charting (rearranging and organising the data according to where it sits within the thematic framework, often grouped by subject or theme area – in the case of VISTA, most often by symptom or groups of related symptoms within larger domains), and mapping-interpretation (builds upon charting to grasp the overall picture of the themes, their interrelations and associations, allowing for phenomenological interpretations). For the purposes of this secondary analysis, these steps were repeated with specific attention to the theme of decreased initiation.
  2. Initiating less (initiates house cleaning less frequently) Initiating only with prompting (only initiates house cleaning when someone prompts them ) Not initiating (prompt or not) but will do activity if assisted ( never initiates house cleaning, but will help out if someone else starts it) Cessation of activity even if prompted (never engages in house cleaning, even if encouraged)
  3. (mean problems = 2.3 ± 1.4) characteristics: mean age 78 ±8 years; 64% women; 64% mild AD
  4. Other activities was usually a reference to activities in general – non specific.
  5. Again, spontaneous reports.
  6. More interest mentioned in leisure and social. Makes a logical sense to us as dressing yourself is less a matter of choice and interest than whether or not you go bowling.
  7. *ongoing work * The one not employed by carer was pt who acknowledged that he initiated less and answered the question “how do you cope with this” by saying he just doesn’t worry (He had put his future with AD in to God’s hand)
  8. 84% of patients describing decreased initiation had at least one goal set of for this.